OptimizeRx Corporation — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. The financial statements are unaudited. OptimizeRx describes itself as a digital health technology company connecting life-sciences organizations, healthcare providers and patients through a point-of-care network.
Financial results
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $13.82 million | $13.98 million | $26.82 million | $27.71 million |
| Gross profit / margin | $7.83 million / 56.6% | $8.99 million / 64.3% | $15.26 million / 56.9% | $17.09 million / 61.7% |
| Operating loss | $4.88 million | $3.91 million | $11.95 million | $7.67 million |
| Net loss | $4.16 million | $3.88 million | $10.56 million | $7.65 million |
| Loss per share, diluted | $0.24 | $0.21 | $0.62 | $0.42 |
- At June 30, cash and cash equivalents were $9.8 million and short-term U.S. Treasury investments were $52.9 million. Current assets were $85.1 million against current liabilities of $5.5 million, giving working capital of $79.6 million and a current ratio of 15.4 to 1.
- The company reported no borrowings; total liabilities were $5.5 million, including approximately $14,000 of lease liabilities. The filing does disclose future minimum partner payments discussed below.
- For the first six months, operating cash flow was negative $2.5 million, versus positive $4.4 million in 2022. Investing activities provided $1.7 million, including net Treasury-bill redemptions; financing used $7.6 million, primarily for share repurchases. Cash declined $8.4 million to $9.8 million.
- Stock-based compensation was $7.9 million in the first half. It is a substantial noncash expense and is relevant when assessing reported losses and dilution.
Changes and management commentary
- Revenue declined 1% in Q2 and 3% in the first half year over year. Management attributed the shortfall to certain non-core business lines, extended medical, legal and regulatory reviews that delayed revenue into the second half, and macroeconomic pressures affecting customers.
- Gross margin fell 7.7 percentage points in Q2 and 4.8 points for the first half. Management cited solution and channel mix, including a lower share of activity through lower-cost channels.
- First-half operating expenses rose about 10% to $27.2 million, mainly due to higher other general and administrative expenses, including increased headcount and investments to support growth and operations. First-half net loss widened by $2.9 million.
- Key commercial indicators weakened: net revenue retention was 89% versus 113%; average revenue per top-20 pharmaceutical manufacturer was $1.97 million versus $2.45 million; and revenue per average full-time employee was $559,646 versus $661,319. Top-20 customer penetration remained 90%, while the top 20’s share of revenue decreased to 58% from 69%.
Outlook, risks and unusual items
- Management believes operating cash generation and existing funds will be sufficient for current operations for the next 12 months, and expects operations to provide funding beyond that period. No specific revenue or earnings guidance is provided.
- Management noted typical industry seasonality, with pharmaceutical brand marketing often strongest in Q4 and the first half generally less active. It also cited slower customer spending and longer sales cycles amid macroeconomic uncertainty.
- The company had $13.3 million of future minimum payments under partner arrangements, expected to be reflected in cost of revenues during 2023–2025.
- The board authorized up to $15 million of repurchases in March 2023. In Q2 the company repurchased 526,999 shares for $7.52 million; approximately $7.49 million remained available under the program at June 30.
- An April CEO equity-award modification created approximately $1.9 million of additional noncash compensation expense to be recognized over three years. The filing also reports $1.3 million of capitalized software costs in progress.
- Disclosure controls were not effective at the reasonable-assurance level due to a previously disclosed material weakness in internal control over financial reporting. Management described remediation work involving third-party service-organization reports and testing.
- The filing lists customer concentration, seasonal demand, prolonged sales cycles, healthcare regulation, platform and partner dependencies, cybersecurity, competition and macroeconomic conditions among relevant risks. It reports no material pending litigation and no material changes to the risk factors in the 2022 Form 10-K.
Important facts for investors to verify
- Whether delayed reviews and non-core business weakness translated into the expected second-half revenue, and whether management provided updated guidance elsewhere.
- Whether margin pressure and weaker retention persist, including the effect of channel mix and customer spending patterns.
- Cash conversion and the impact of partner prepayments, revenue-share timing and the $13.3 million minimum-payment commitments.
- Progress in remediating the material control weakness and whether controls become effective.
- Remaining repurchase authorization, future cash needs and the effect of stock-based compensation and share awards on dilution.